We are live on
!
Find out more
OFM
Omega Fund Management Portfolio holdings
AUM
$186M
1-Year Est. Return
155.23%
This Fund
S&P 500
This Quarter
Est. Return
+20.53%
1 Year Est. Return
+155.23%
3 Year Est. Return
+106.31%
5 Year Est. Return
+162.6%
10 Year Est. Return
+764.79%
AUM
$160M
AUM Growth
+$6.4M
(+4.2%)
Cap. Flow
-$6.43M
Cap. Flow
% of AUM
-4.01%
Top 10 Holdings %
Top 10 Hldgs %
99.56%
Holding
11
New
–
Increased
–
Reduced
3
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KYNB
Kyntra Bio
KYNB
|
+$5.15M |
| 2 |
PVLA
Palvella Therapeutics
PVLA
|
+$1.21M |
| 3 |
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
|
+$72.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
LBC
GWCM
FWM
LOIP
TFA
NCM
GPI
MWM
Omega Fund Management's Q2 2017 Portfolio in Review
As of Q2 2017, Omega Fund Management held 11 positions worth $160M, up 4.2% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Omega Fund Management withdrew a net $6.43M in Q2 2017, reducing 3 holdings. Its largest reduction was Kyntra Bio, cutting an estimated $5.15M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Omega Fund Management's biggest Q2 2017 reduction was Kyntra Bio, cutting an estimated $5.15M.
- Omega Fund Management's ten largest holdings make up 100% of its $160M portfolio in Q2 2017.
- Omega Fund Management opened 0 new positions and closed 0 in Q2 2017.
- Omega Fund Management's portfolio value rose 4.2% quarter-over-quarter to $160M.
Based on Omega Fund Management's 13F filing for Q2 2017, filed 26 Jul 2017.